Results 141 to 150 of about 141,957 (168)

Impact of Genetic Testing Family Screening in Hereditary Transthyretin Amyloidosis. [PDF]

JACC CardioOncol
Mora-Ayestarán N, Gil-Llopis C, González-Maniega C, Piovano MV, Águila-Gordo D, Briceño A, González-Vioque E, Domínguez F, González-López E, Garcia-Pavia P.   +9 more
europepmc   +1 more source

Clinical and genetic features of hereditary transthyretin amyloidosis with polyneuropathy in China: insights from case analysis and literature review. [PDF]

Front Genet
Yuan X, Lv Y, Wang X, Han B, Xie B.
europepmc   +1 more source

Comments on "Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials". [PDF]

Ther Adv Cardiovasc Dis
Sharma A, Vadhithala V, Kumar A, Verma S, Katkuri SN.   +4 more
europepmc   +1 more source

First-Generation TTR Silencing Therapies in Hereditary Transthyretin Amyloidosis With Polyneuropathy: Real-World Insights From a German Single-Referral Center. [PDF]

Eur J Neurol
Koch MS, Siepen FAD, Hegenbart U, Schönland S, Weiler M.   +4 more
europepmc   +1 more source

Genetic testing and evidence of a founder mutation in a hotspot for hereditary transthyretin amyloidosis. [PDF]

Sci Rep
Ventayol-Guirado M, Cisneros-Barroso E, Ribot-Sanso MA, Gonzalez-Moreno J, Losada I, Ripoll-Vera T, Pons J, Fortuny E, Bosch T, Figuerola A, Descals C, Montala JC, Alvarez-Rubio J, Hernandez-Rodriguez J, Lustre-Rodriguez J, Llull-Alberti MV, Jimenez-Barcelo JA, Asensio-Landa VJ, Torres-Juan L, Martinez-Lopez I, Buades-Reines J, Heine-Suñer D.   +21 more
europepmc   +1 more source

A new staging system for hereditary transthyretin amyloidosis in the era of specific amyloidosis therapies. [PDF]

ESC Heart Fail
Neculae G, Zaroui A, Adam R, Kharoubi M, Funalot B, Coriu D, Jurcut R, Damy T.   +7 more
europepmc   +1 more source

Long-Term Peritoneal Dialysis in Hereditary Transthyretin Amyloidosis: A Case Report and Management Challenges. [PDF]

Cureus
Fernandes V, Paulo N, Silva R, Oliveira A, Beco A, Pestana M.   +5 more
europepmc   +1 more source

THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis

Current Medical Research and Opinion, 2013
Background: Transthyretin (TTR) amyloidosis is a rare, life-threatening, systemic, autosomal dominant condition occurring in adults, with two main forms: hereditary (associated with TTR gene mutations) and wild-type.
Mathew S Maurer, Ole B. Suhr
exaly   +2 more sources